Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study

PDF  |  How to cite

Oncotarget. 2022; 13:1307-1307. https://doi.org/10.18632/oncotarget.28317

Metrics: PDF 155 views  |   ?  

Silvia P. Corona1, Fabiola Giudici1,2, Guy Jerusalem3, Eva Ciruelos4, Carla Strina5, Marianna Sirico6, Ottavia Bernocchi1, Manuela Milani5, Martina Dester5, Nicoletta Ziglioli5, Giuseppina Barbieri5, Valeria Cervoni5, Filippo Montemurro7 and Daniele Generali1,5

1Department of Medicine, Surgery and Health Sciences, University of Trieste, Cattinara Hospital, Trieste, Italy
2Unit of Biostatistics, Epidemiology and Public Health, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy
3CHU Sart Tilman Liège and Liège University, Liège, Belgium
4Hospital Universitario 12 de Octubre, Madrid, Spain
5Multidisciplinary Unit of Breast Pathology and Translational Research, Cremona Hospital, Cremona, Italy
6Università Cattolica del Sacro Cuore, Roma, Italy
7Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy

Published: December 06, 2022

Copyright: © 2022 Corona et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: Written informed consent was obtained from all patients. The study protocol was approved by an independent ethics committee or institutional review board at each site.

Original article: Oncotarget. 2020; 11:2172–2181. DOI: https://doi.org/10.18632/oncotarget.27612

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28317